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Abstract
The mechanisms that regulate hematopoietic stem cell (HSC) dormancy and self-renewal are well established and
are largely dependent on signals emanating from the HSC niche. Recently, we found that prostate cancer (PCa)
cells target the HSC niche in mouse bone marrow (BM) during metastasis. Little is known, however, as to how the
HSC nichemay regulate dormancy in cancer cells. In this study, we investigated the effects of TANK binding kinase 1
(TBK1) on PCa dormancy in the BM niche. We found that binding with niche osteoblasts induces the expression
of TBK1 in PCa cells PC3 and C4-2B. Interestingly, TBK1 interacts with mammalian target of rapamycin (mTOR)
and inhibits its function. Rapamycin, an mTOR inhibitor, induces cell cycle arrest of PCa cells and enhances
chemotherapeutic resistance of PCa cells. As a result, the knockdown of TBK1 decreases PCa stem-like cells and
drug resistance in vitro and in vivo. Taken together, these results strongly indicate that TBK1 plays an important role
in the dormancy and drug resistance of PCa.
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Introduction
TANK binding kinase 1 (TBK1) is a noncanonical IκB kinase (IKK)
family member that mediates the innate immune response. Toll-like
receptors (TLR3 and TLR4) and the cytosolic receptors (RIG-I and
MDA-5) recognize bacterial lipopolysaccharide or viral dsRNA and
induce the phosphorylation of TBK1 [1]. Activated TBK1 then
phosphorylates interferon regulatory factors (IRF3 and IRF7), medi-
ating IRF dimerization, nuclear translocation, and transcription of
target genes, such as interferon beta (IFN-β) and RANTES [2–5].
In cancer, emerging evidence demonstrates that TBK1 plays an impor-
tant role in angiogenesis, transformation, and cell survival [6,7]. TBK1
is induced under hypoxic conditions, predominantly increased in solid
tumors compared with normal tissue, and promotes secretion of pro-
angiogenic factors, such as RANTES and interleukin 8 (IL-8), resulting
in proliferation of endothelial cells [8]. Activation of TBK1 by RalB-
mediated Sec5/TBK1 complex assembly is required for oncogenic Ras-
induced transformation and tumor cell survival [9]. Systematic RNA
interference screening reveals that TBK1 is essential for survival of
oncogenic KRAS-driven cancer cells [10]. In addition, recent studies
have identified that TBK1 directly phosphorylates AKT to inhibit
apoptosis and support oncogenic transformation [11,12].
The mammalian target of rapamycin (mTOR) is the catalytic sub-
unit of two distinct signaling complexes, mTOR complex 1 (mTORC1)
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and mTOR complex 2 (mTORC2) [13]. mTORC1, which consists of
mTOR, raptor, deptor, mLST8, and PRAS40, activates ribosomal S6
kinase (S6K) and inactivates eukaryotic initiation factor 4E binding
protein 1, stimulating protein synthesis, cell proliferation, and cell cycle
progression [13–16]. In contrast, mTORC2, which contains mTOR,
rictor, deptor, mLST8, and mSIN1, phosphorylates AKT and protein
kinase C–α, promoting cell survival and cytoskeleton reorganization
[17,18]. Rapamycin directly binds to mTORC1 and inhibits mTORC1
activity [14]. However, mTORC2 is insensitive to rapamycin, although
prolonged treatment can inhibit mTORC2 in many cell types [19].
Recent studies have shown that both TBK1 and mTORC2 phos-
phorylate AKT at S473 [11,12,20] and that mTORC1 inhibition
increases AKT phosphorylation at S473 [21]. These studies led us
to investigate the relationship between TBK1 and mTOR. In this
study, we found that the binding of prostate cancer (PCa) cells to
osteoblasts in the hematopoietic stem cell (HSC) niche induces the
expression of TBK1 in PCa cells. Interestingly, TBK1 inhibits
mTOR signaling pathway. Furthermore, rapamycin, an mTOR
inhibitor, induces cell cycle arrest of PCa cells and anticancer drug
resistance in PCa cells. Finally, we demonstrate that TBK1 enhances
the PCa stem-like cells and drug resistance in vitro and in vivo. Taken
together, these results strongly indicate that TBK1 plays an impor-
tant role in dormancy and drug resistance of PCa.
Materials and Methods
Cell Cultures
Human PCa line PC3 and human breast cancer cell line MDA-
MB-231 were obtained from the American Type Culture Collection
(Rockville, MD). The metastatic subline LNCaP was originally iso-
lated from a lymph node of a patient with disseminated bony and
lymph node involvement and the C4-2B subline established by pas-
sage in vivo. PC3Luc cells were constructed by stably transfecting PC3
cells with a luciferase or green fluorescent protein (GFP) construct.
PCa cells or MDA-MB-231 cells were grown in RPMI 1640 medium
(Invitrogen, Carlsbad, CA) supplemented with 10% FBS and 1%
penicillin/streptomycin (P/S). The murine bone marrow (BM)–
derived stromal cell line ST2was grown in α–minimum essential medium
(Invitrogen) with 10% heat-inactivated FBS and 1% P/S. 293T cells
were grown in Dulbecco’s modified Eagle’s medium (Invitrogen) with
10% FBS and 1% P/S.
RNA Interference
PC3 or PC3Luc cells were transfected with pGIPZ lentiviral
shRNA constructs (Vector Core, University of Michigan, Ann
Arbor, MI) for scrambled (RHS4346) and human TBK1 (RHS4430-
99299280), according to themanufacturer’s instructions. Plasmids were
co-transfected with psPAX2 and pMD2.G into HEK-293T cells using
CaPO4. Supernatants were collected after 60 hours and used to infect
cells. Infected cells were selected for 7 days in RPMI 1640medium con-
taining 1 μg/ml puromycin, and the expression of TBK1 was analyzed
by Western blot analysis.
Site-Directed Mutagenesis
TBK1 plasmid was purchased from Addgene (Cambridge, MA).
Kinase-dead (K38A) or TOR signaling (TOS) motif mutant
(F638A) TBK1 plasmid was generated using the Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA) according to the manu-
facturer’s instructions.
In Vivo Isolation of Disseminated Human PCa Cells from
Murine Bone Marrow
Intracardiac injections of PCa cells (1 × 106 cells) were performed
into male CB.17.SCID mice (4-6 weeks of age; Charles River Labora-
tories, Wilmington, MA). After 24 hours, BM cells were flushed from
the femurs, tibias, and humeri. Cells were incubated with a Lineage
Cell Depletion Kit magnetic labeling system with biotinylated anti-
Lineage [CD5, CD45R (B220), CD11b, Gr-1 (Ly-6G/C), and Ter-
119] antibody cocktail and anti-Biotin MicroBeads (Miltenyi Biotec,
Auburn, CA) and then enriched for murine Lineage negative popula-
tion using an AutoMACS machine (Miltenyi Biotec). Enriched cells
were incubated with fluorescein isothiocyanate–HLA-ABC antibody
(BioLegend, San Diego, CA), PE–anti-CD133 antibody (Miltenyi
Biotec), and APC–anti-CD44 antibody (BD Biosciences, San Diego,
CA) for 20 minutes at 4°C. The CD133+/CD44+ and CD133−/
CD44− fractions were sorted by gating on HLA-ABC–positive cells
(human cells) with a FACSAria High-Speed Cell Sorter (BD Bio-
sciences). All experimental procedures were approved by the University
of Michigan Committee for the Use and Care of Animals.
FACS Analysis
For stem-like cell counting, cells were incubated with PE–anti-
CD133 antibody (Miltenyi Biotec) and APC–anti-CD44 antibody
(BD Biosciences) for 20 minutes at 4°C. For cell cycling analysis,
cells were fixed, permeabilized with Perm/Wash Buffer (BD Bio-
sciences), and incubated with polyclonal anti-Ki67 antibody (Abcam,
Cambridge, MA) for 30 minutes at 4°C. Subsequently, the cells were
incubated with PE-coupled secondary antibodies (Abcam). The
CD133+/CD44+ or Ki67− fraction was analyzed with a FACSAria
High-Speed Cell Sorter (BD Biosciences).
Quantitative Reverse Transcription–Polymerase
Chain Reaction
Total RNA was extracted from cells using the RNeasy mini or
micro kit (Qiagen, Valencia, CA) and converted into cDNA using
a First-Strand Synthesis Kit (Invitrogen). For isolated CD133+/
CD44+ PCa cells from the BM of mice, cDNA was boosted using a
PreAmp Master Mix (Applied Biosystems, Foster City, CA). Quanti-
tative polymerase chain reaction (qPCR) was performed on an ABI
7700 sequence detector (Applied Biosystems) using TaqMan Universal
PCR Master Mix Kit (Applied Biosystems) according to the manufac-
turer’s instructions. TaqMan MGB probes (Applied Biosystems) were
given as follows: human TBK1 (Hs00179410_m1) and human IKKE
(Hs01063858_m1). Human β-actin (Hs99999903_m1) was used as
an internal control for the normalization of target gene expression.
Western Blot Analysis
Whole-cell lysates were prepared from cells, separated on 10%
sodium dodecyl sulfate–polyacrylamide gel, and transferred to poly-
vinylidene difluoride (PVDF) membrane. The membranes were incu-
bated with 5%milk for 1 hour and incubated with primary antibodies
overnight at 4°C. Primary antibodies used were given as follows: poly-
clonal anti-mTOR (1:1000; Cell Signaling Technology, Danvers,
MA), polyclonal anti-raptor (1:1000; Cell Signaling Technology), poly-
clonal anti-TBK1 (1:1000; Cell Signaling Technology), polyclonal
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anti–phospho-p70S6K (1:500; Cell Signaling Technology), polyclonal
anti-p70S6K (1:1000; Cell Signaling Technology), and monoclonal
anti–FLAG M2 (1:2000; Sigma-Aldrich, St Louis, MO). Blots were
incubated with peroxidase-coupled secondary antibodies (Promega,
Madison, WI) for 1 hour, and protein expression was detected with
SuperSignal West Pico Chemiluminescent Substrate (Thermo Sci-
entific, Rockford, IL). Membranes were reprobed with polyclonal
anti–β-actin antibody (1:1000; Cell Signaling Technology) to con-
trol for equal loading.
Immunofluorescence Staining
PCa cells and PCa tissue microarrays (TMA; PR954; US Biomax,
Rockville, MD) were used for immunostaining. Cells were fixed with
4% paraformaldehyde and permeabilized with 0.2% Triton X-100
(Sigma-Aldrich) in PBS. TMA sections were unmasked with pepsin
solution (Lab Vision, Fremont, CA) at 37°C for 15 minutes and bal-
anced with phosphate-buffered saline (PBS) plus 0.2% Triton X-100
for 5 minutes. Cells and TMA sections were blocked with Image-iT
FX signal enhancer for 30 minutes and incubated for 2 hours at room
temperature with primary antibodies combined with reagents of
Zenon Alexa Fluor 488 (green) or 555 (red) labeling kit (Invitrogen).
Polyclonal anti-TBK1 (Cell Signaling Technology), polyclonal anti-
mTOR (Cell Signaling Technology), and monoclonal anti–phospho-
p70S6K (Millipore, Temecula, CA) were used as primary antibodies.
After washing with PBS, cells and TMA sections were mounted with
ProLong Gold antifade reagent with 4′,6-diamidino-2-phenylindole
(DAPI; Invitrogen). Images were taken with Olympus FV-500
confocal microscope.
Cell Survival Assay
PCa cells (1 × 105) were seeded onto 12-well culture plates and
then treated with anticancer drugs and/or rapamycin at 37°C for
the indicated time. The final concentration of anticancer drugs used
was given as follows: 10 μg/ml cisplatin, 500 nM doxorubicin, 100 nM
taxol, 100 μg/ml 5-fluorouracil, and 100 ng/ml taxotere. Viability of
the cells was determined by trypan blue assay. Apoptosis was measured
Figure 1. TBK1 and IKKE are increased by osteoblast binding. (A) PC3-GFP cells were cultured for 24 and 48 hours on tissue culture
plastic or BM stromal cell ST2 (OB). The dormant population was examined by flow cytometry using Ki67 antibody. (B) PC3-GFP cells
were cultured for 72 hours with/without taxotere on tissue culture plastic or ST2 cells. Cell death was measured using flow cytometry
with Annexin V staining. (C and D) PC3 cells or (E and F) C42B cells were cultured for 48 hours with/without taxotere on tissue culture
plastic or ST2 cells. Expression of TBK1 and IKKE was quantified by qPCR. The results were normalized to β-actin. The results represent
mean ± SD values from triplicate assays, and the experiments were performed twice.
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by flow cytometry using PE Annexin V Apoptosis Detection Kit I
(BD Biosciences) according to the manufacturer’s instructions. Assays
were performed in triplicate, and the results are representative of three
independent experiments.
Co-Immunoprecipitation Assays
Cells were lysed in 0.3% CHAPS buffer (40 mM Hepes, 120 mM
NaCl, 0.3% CHAPS, 1 mM PMSF, 1 μg/ml leupeptin, 2 μg/ml
aprotinin, and 1 μg/ml pepstatin) on ice for 30 minutes. Lysates con-
taining 1 mg of total protein were precleared with 30 μl of Protein-A/
G Plus-Agarose (Santa Cruz Biotechnology, Santa Cruz, CA).
Cleared lysates were incubated with 2 μg of monoclonal anti–FLAG
M2 antibody (Sigma-Aldrich) or 2 μg of polyclonal anti-TBK1 anti-
body (Cell Signaling Technology) or 2 μg of normal IgG antibody
(Santa Cruz Biotechnology) for 3 hours at 4°C and then incubated
with 30 μl of Protein-A/G Plus-Agarose for 1 hour at 4°C. Immuno-
precipitates were washed four times in lysis buffer and analyzed by
Western blot analysis.
In Vivo Dormancy Assays
All experimental procedures were approved by the University of
Michigan Committee for the Use and Care of Animals. Lumbar ver-
tebrae were isolated from 4- to 7-day-old mice. The vertebrae were
sectioned into single vertebral bodies (vossicles). Severe combined-
immunodeficiency (SCID) mice were used as transplant recipients.
Two vossicles per mouse were implanted into subcutaneous pouches.
Before implantations, PC3Luc cells containing scrambled or TBK1
shRNA plasmids were introduced into the vossicles (10,000 cells/
10 μl of PBS). Mice were treated with taxotere (12 mg/kg, 1×/week)
or vehicle for 3 weeks and imaged for 9 weeks by bioluminescent
imaging (BLI). BLI was performed through the University of
Michigan Small Animal Imaging Resource facility. Briefly, mice were
injected with luciferin (40 mg/ml) by intraperitoneal injections, and
ventral images were acquired 10 minutes after injection under 1.75%
isoflurane/air anesthesia. Total tumor burden of each animal was cal-
culated using regions of interest that encompassed the entire animal.
After 9 weeks, tumor volumes were calculated using the following
formula: V = the shortest diameter × the longest diameter × height.
In Vivo Tumor Growth and Angiogenesis Assays
PC3 cells (5 × 105) were implanted in the flanks of SCID mice.
Mice were treated with rapamycin (1 mg/kg, 2×/week) or vehicle for
3 weeks. After 4 weeks, the tumor volumes were calculated and
tumors were fixed. Histologic sections were incubated in antigen
retrieval solution for 30 minutes at 90°C, followed by incubation
with polyclonal anti-human factor VIII antibody (Lab Vision) over-
night at 4°C. The number of microvessels in six random fields were
counted under light microscope at ×200 magnification.
Figure 2. TBK1 is highly expressed in PCa cells. (A) The expression of TBK1 and IKKE was analyzed by Western blot analysis in human
PCa cell lines PC3 and C42B and human breast cancer cell line MDA-MB-231 (MDA-231). (B) PCa TMA sections were analyzed by
immunofluorescence staining with TBK1 antibody. Representative micrographs of normal prostate and PCa (Gleason score) and bone
metastases at ×60. (C) Staining intensity was scored blindly as absent (1), weak (2), moderate (3), strong (4), and very strong (5).
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Statistical Analyses
Results are presented as means ± SD. Significance of the difference
between two measurements was determined by unpaired Student’s
t test, and multiple comparisons were evaluated by the Newman-Keuls
multiple comparison test. Values of P < .05 were considered significant.
Results
Expression of TBK1 and IKKE in PCa Cells is Increased after
Binding to Osteoblasts and by Anticancer Drug Treatment
Recently, we reported that PCa cells target the HSC niche in
mouse BM during metastasis [22]. Because binding to the BM niche
induces dormancy and long-term survival of HSCs [23], we hypoth-
esized that targeting the BM niche also induces the dormancy of PCa
cells. To determine if binding with niche cells promotes PCa dor-
mancy, PC3 cells were co-cultured with murine BM-derived stromal
cell line ST2 cells and then the cell cycle of PCa cells was analyzed by
flow cytometry using Ki67 antibody. As expected, PCa cell binding
to ST2 cells increased the frequency of the dormant population
(Ki67 negative; Figure 1A). In addition, PCa cell binding to ST2
cells significantly prevented cell death induced by the administration
of taxotere (Figure 1B).
Accumulating evidence demonstrates that TBK1 and IKKE play
important roles in tumorigenesis and survival [6,9,10,24,25] and
are expressed by tumor cells under stressful growth conditions [8]
including those that predominate in the HSC niche [26–28]. To
evaluate whether the binding of PCa cells to niche osteoblasts in-
duces the expression of TBK1 and IKKE in PCa cells, PCa cells were
co-cultured with ST2 cells and then analyzed by qPCR. As shown in
Figure 1, C to F , the expression of TBK1 and IKKE in PCa cells was
increased following binding to ST2 cells. Interestingly, binding of
PCa cells to ST2 cells significantly induced the expression of
TBK1 and IKKE when the PCa cells were treated with taxotere (Fig-
ure 1, C–F ).
TBK1 Inhibits mTOR Signaling
At present, little is known about the function of TBK1 and IKKE
in PCa cells. Therefore, we first examined the extent to which TBK1
and IKKE are expressed in PCa cells. Western blot analysis showed
that TBK1 is well expressed in PCa cells (PC3 and C42B) compared to
breast cancer cells (MDA-MB-231) and that IKKE is poorly expressed
in PCa cells (Figure 2A). Therefore, we focused our further studies on
TBK1 to understand how PCas become dormant in the BM. As shown
in Figure 2, B and C , TBK1 expression was also increased in a tumor
stage–dependent manner in human prostate tumor tissues.
To explore the function of TBK1 in PCa cells, TBK1 was stably
knocked down using lentiviral shRNA in PC3 cells. Surprisingly,
TBK1 knockdown induced the phosphorylation of p70S6K, indica-
tive of mTOR activation (Figure 3A). Moreover, we found that
TBK1 is co-localized with mTOR (Figure 3B). To further confirm
Figure 3. TBK1 inhibits mTOR signaling. (A) PC3 cells were infected with lentivirus containing scrambled or TBK1 shRNA plasmid,
selected with puromycin, and analyzed by Western blot analysis using antibodies against p-p70S6K, TBK1, or β-actin. (B) PC3 cells were
co-immunostained with TBK1 (green) and mTOR (red) antibodies. Merged image (yellow) shows co-localization of TBK1 and mTOR.
(C) 293T cells were transfected with a plasmid encoding Flag-TBK1. Cell lysates were immunoprecipitated with Flag antibodies or nor-
mal mouse IgG as negative control and analyzed by Western blot analysis using antibodies against mTOR, raptor, and TBK1. (D) PC3 cell
lysates were immunoprecipitated with TBK1 antibodies or normal rabbit IgG as negative control and analyzed by Western blot analysis
using antibodies against mTOR, raptor, and TBK1. (E) C4-2B cells were transfected with control empty vector (Con) or a plasmid encoding
wild-type (WT) or Kinase-dead (KD) or TOSmotif mutant TBK1 (mTOS). Cell lysates were analyzed byWestern blot analysis using antibodies
against p-p70S6K, p70S6K, Flag, and β-actin.
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the interaction, a co-immunoprecipitation assay was performed in
TBK1 overexpressing 293T cells (293T/TBK1) and PC3 cells. Indeed,
mTOR and raptor interacted with overexpressed TBK1 in 293T cells
(Figure 3C) or endogenous TBK1 in PC3 cells (Figure 3D). In C42B
cells, overexpression of wild-type TBK1 blocked the phosphorylation of
p70S6K, whereas overexpression of kinase-dead (K38A) or TOR
signaling (TOS) motif mutant (F638A) TBK1 could not inhibit the
phosphorylation (Figure 3E). More importantly, the phosphorylation
of p70S6K in human clinical tissues was decreased in a tumor stage–
dependent manner (Figure W1, A and B), showing an inverse cor-
relation with TBK1 (Figure 2, B and C ). These results suggest that
TBK1 expression may be important for regulation of mTOR signaling
in PCa cells.
mTOR Inhibition Induces Dormancy and
Drug Resistance in PCa Cells
To investigate whether mTOR signaling is involved in dormancy,
we used rapamycin, a specific inhibitor of mTOR. Although rapa-
mycin clearly reduced tumor growth and angiogenesis in PC3 cells
implanted in mice (Figure W2, A–C ), mTOR inhibition by rapamy-
cin significantly increased the dormant population (Ki67 negative) in
a time-dependent manner in both PC3 cells (Figure 4A) and C42B
cells (Figure 4B). To determine if the dormant PCa cells are resistant
to chemotherapy, PCa cells were pretreated with rapamycin for 3 days
and then treated with several anticancer drugs. Indeed, PCa cells pre-
treated with rapamycin led to the reduction of cell death (Figure 4, C
and E ) and apoptosis (Figure 4, D and F ).
TBK1 Is Important for PCa Stem-Like Cells, Drug Resistance,
and Dormancy
We further explored if TBK1 plays an important role in PCa
stem-like cells because dormant population may contribute to the stem
cell–like properties. PCa stem-like cells were sorted as CD133+/CD44+
cells. Isolated CD133+/CD44+ cells and CD133−/CD44− cells were
co-cultured on ST2 cells and then analyzed for the expression of
TBK1 by qPCR. As shown in Figure 5, A and B, the expression
Figure 4. mTOR inhibition induces dormancy and drug resistance in PCa cells. (A) PC3 or (B) C42B cells were treated with 10 nM
rapamycin for 0, 24, 48, and 96 hours. The dormant population was examined by flow cytometry using Ki67 antibody. (C) PC3 cells
or (E) C42B cells were treated with the indicated anticancer drugs for 2, 3 and 4 days in the presence and absence of rapamycin. Cell
death was measured by trypan blue assay. (D) PC3 cells or (F) C42B cells were treated with the indicated anticancer drugs for 72 hours
in the presence and absence of rapamycin. Cell death was measured by flow cytometry with Annexin V staining. All results represent
average mean ± SD values from triplicate assays, and the experiments were performed twice.
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of TBK1 was increased by binding to ST2 cells in both CD133+/
CD44+ cells and CD133−/CD44− cells. However, when CD133+/
CD44+ cells and CD133−/CD44− cells were isolated from mouse
BM niche (Figure 5C ), the expression level of TBK1 in CD133+/
CD44+ cells was significantly higher than that in CD133−/CD44− cells
(Figure 5, D and E).
Next, to investigate the function of TBK1 in PCa stem-like cells,
PC3 cells containing TBK1 or scrambled shRNA (Figure 3A) were
cultured for 3 days in the presence and absence of rapamycin and
analyzed by flow cytometry. Interestingly, TBK1 knockdown
decreased the number of CD133+/CD44+ cells in PCa cells (Figure 6,
A and B ) and increased CD133−/CD44− cell populations (Figure 6,
C and D). In contrast, mTOR inhibition by rapamycin increased the
population of CD133+/CD44+ cells in PCa-scrambled shRNA cells
and also blocked the reduction of stem-like cells in PC3-TBK1
shRNA cells. To examine the effect of TBK1 on drug resistance, these
cells were treated for 3 days with taxotere in the presence and absence
of rapamycin and analyzed by a cell death assay. As expected, TBK1
knockdown significantly increased cell death by taxotere (Figure 6E ).
These data suggest that TBK1 is important for PCa stem-like cells
and drug resistance.
Finally, we examined whether TBK1 is also critical for the dor-
mancy of PCa in vivo. PC3Luc cells containing TBK1 or scrambled
shRNA were injected into vertebral bodies (vossicles) derived from
mice and then transplanted into subcutaneous pouches of SCID
mice. Mice bearing tumors were injected intraperitoneally with
taxotere for 3 weeks. Tumor regrowth was induced by stopping
treatment. BLI was performed every week to evaluate luciferase activ-
ity in the implanted vossicles. After 9 weeks, tumor volume was
measured. Taxotere treatment inhibited tumor growth for 4 weeks
(Figure 7A). As shown in Figure 7, A to D, TBK1 knockdown inhib-
ited tumor recurrence after 4 weeks, while scramble shRNA failed to
prevent PCa from the regrowth. These results suggest that TBK1 is
important for the establishment of dormancy by PCa and drug resis-
tance in vivo.
Discussion
In this study, we investigated the mechanisms that regulate dormancy
of PCa in the BM. We found that PCa binding to components of the
HSC niche increases the dormant population of PCa and their ability
to withstand multiple chemotherapeutic insults. As part of the pro-
cess, it was observed that the expression of TBK1 in PCa cells was
increased following binding and in response to the chemotherapeutic
agent taxotere.
The disseminated tumor cells (DTCs) from PCa that lodge or
home to the marrow appear to be an early feature of “localized” dis-
ease. From an evolutionary standpoint, DTCs must have the capacity
to not only escape from the primary tumor but also survive in the
circulation and engage the marrow microenvironment in such a
Figure 5. TBK1 is highly expressed in PCa stem-like cells on mouse BM niche. (A) PC3 or (B) C42B cells were sorted with APC–anti-CD44
and PE–anti-CD133 antibodies. The CD133+/CD44+ and CD133−/CD44− cells were cultured for 48 hours on tissue culture plastic or ST2
(OB) cells. Expression of TBK1 was quantified by qPCR. The results were normalized to β-actin. (C) Experimental model of isolation of
PCa stem-like cells in vivo. The CD133+/CD44+ and CD133−/CD44− cells were sorted from BM cells of (D) PC3- or (E) C4-2B-injected
SCID mice. Expression of TBK1 was quantified by qPCR. The results were normalized to β-actin. All results represent average values from
triplicate assays, and the experiments were performed twice.
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fashion to establish a foothold in the harsh marrow microenvironment.
On the basis of the clinical course of metastatic PCa, two apparent
phases of growth were seen in patients who ultimately present with
end-stage disease: a latent or dormant phase that may be followed by
a proliferative phase. Yet howDTCs switch between these two phases is
not clear. One hypothesis is that DTCs are normally metabolically
active but may have exited the cell cycle in response to space or resource
competition. Proliferative arrest has also been observed in cells in which
p38 activity exceeds extracellular signal-regulated kinase (ERK)-kinase
expression [29]. An alternative explanation for dormancy is that pro-
liferation and cell death rates are stably coupled. Yet it also remains
unclear what regulates the uncoupling of growth from apoptosis. In the
context of dormancy in the marrow regulated by the HSC niche, both
hypotheses can be accommodated. In the first case, changes in systemic or
local host-derived signals or even DTC-secreted paracrine signals that
regulate niche activity may tip the balance in favor of proliferative
growth. In the second instance, DTC migration or movement away
from the niche signals may trigger a slow or even sustained growth by
uncoupling apoptosis from proliferation. The role of TBK1 in each of
these models of dormancy is possible; however, our data suggest that
TBK1 plays a role in DTCs that are likely to have exited the cell cycle
induced by niche engagement, although further studies are needed.
Tumor dormancy is defined by the persistence of minimal residual
tumor cells over an extended period of time. Experimental and lim-
ited clinical data suggest that dormant tumor cells exist in a non-
proliferative state having exited the cell cycle. As many conventional
anticancer drugs target fast growing cancer cells, dormant cancer cells
are thought to be resistant to multiple drugs that ultimately can lead to
Figure 6. TBK1 is important for PCa stem-like cells and drug resistance. PC3 cells were infected with lentivirus containing scrambled or
TBK1 shRNA plasmid, selected with puromycin, and then cultured for 3 days in the presence and absence of rapamycin. The CD133+/
CD44+ (A and B) and CD133−/CD44− (C and D) cells were analyzed by flow cytometry. (E) PC3 cells containing TBK1 or scramble shRNA
were treated for 72 hours with taxotere in the presence and absence of rapamycin. Cell death was measured by the trypan blue assay. All
results represent mean ± SD values from triplicate assays, and the experiments were performed twice.
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disease recurrence [30,31]. Like HSCs, the inactivation of oncogenes
includingMYC induces tumor dormancy even if this results in terminal
differentiation, senescence, and apoptosis [32–34]. Moreover, stress
signaling resulting in p38 induction regulates cell cycle arrest and dor-
mancy of cancer cells, whereas mitogenic signaling pathway by ERK
promotes proliferation and tumorigenicity [29,35]. Yet despite these
insights, when compared with HSC quiescence, little is known regard-
ing the molecular mechanism that regulates cancer cell dormancy.
The regulation of dormancy or quiescence is essential for the long-
term survival of HSCs. Emerging evidence demonstrates that key cell
cycle regulators including p21Cip1, Bmi1, and c-Myc play important
roles in HSC maintenance by self-renewal and quiescence [23,36,37].
The absence of cell cycle inhibitors (tumor suppressors), or the
increase of cell cycle activators (oncogenes), results in HSC hyper-
proliferation, terminal differentiation, and ultimately exhaustion.
Interestingly, recent mouse studies have shown that deletion of neg-
ative regulators of mTOR signaling including TSC1 [38,39], PTEN
[40,41], Fbxw7 [42], PML [43], and Lkb1 [44–46] also results in
defective HSC quiescence, defects in long-term repopulating abilities,
and HSC depletion. Furthermore, Castilho et al. [47] reported that
the activation of mTOR by Wnt1 mediates both hair follicle hyper-
proliferation and epidermal stem cell exhaustion, suggesting that
mTOR signaling also plays an important role in self-renewal and
quiescence of other stem cell systems.
TBK1 participates in the signaling pathway of TLRs. TLRs are
expressed in hematopoietic lineage cells and play a critical role in
the activation of innate immunity by recognizing pathogens. TLR
signaling also promotes adaptive immune responses by activating
immune cells through the secretion of proinflammatory cytokines.
Recent studies demonstrate that TLRs are expressed not only in
immune cells but also in a variety of cancer cells and that TLR
expression induces nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-κB) signaling and stress kinase signaling (p38 and
JNK) and contributes to tumorigenesis by cell survival, chemoresis-
tance, immune evasion, and metastasis [48]. Interestingly, González-
Reyes et al. [49] found that prostate tumors with high TLR3 or
TLR9 expression levels were highly associated with a higher proba-
bility of biochemical recurrence, even though Paone et al. [50]
showed TLR3-mediated apoptosis and proliferation inhibition in
human PCa.
To investigate how TBK1 supports or activates PCa dormancy,
TBK1 expression in PCa was downregulated by shRNA. We found
that TBK knockdown induces the activation of mTOR signaling and
decreased PCa stem-like cells and chemosensitivity in PC3 cells.
Figure 7. TBK1 is important for tumor dormancy in vivo. (A) PC3Luc cells were infected with lentivirus containing scrambled or TBK1
shRNA plasmid. After selection, cells were injected into mouse vossicles and transplanted into SCID mice. Mice were treated with
taxotere or vehicle for 3 weeks. (A) BLI of mice was performed for 9 weeks (n = 9/group). Arrows show taxotere treatment. Represen-
tative mice were shown in B. (C and D) After 9 weeks, tumor volume was measured and quantified.
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Moreover, the mTOR inhibitor rapamycin limits the effects of TBK
knockdown, suggesting that the inhibition of mTOR signaling by
TBK1 is helpful for the PCa stem-like cells and the chemoresistance.
Although oncogenic activation of mTOR signaling contributes to
tumor growth, survival, and proliferation [51], there is emerging
evidence that the inhibition of mTOR signaling is important for
tumor dormancy, chemoresistance, and maintenance of cancer stem–
like cells. The tumor suppressor ARHI induces autophagy by inhibiting
mTOR, and this autophagy contributes to the survival of dormant
ovarian cancer cells [52]. In TSC1- and TSC2-deficient mouse embry-
onic fibroblasts or TSC2 knockdown cancer cell lines, upregulated
mTOR activity increases cell death by anticancer drugs or tumor necro-
sis factor alpha (TNF-α) through the inhibition of NF-κB signaling
and the rapamycin-mediated inhibition of mTOR signaling restored
NF-κB activation and cell survival [53]. Moreover, rapamycin up-
regulates the cancer stem cell marker CD133 in gastric, colorectal,
and lung cancer cell lines [54]. Yang et al. [55] also showed that
rapamycin enhanced the level of CD133 and stem cell–associated
genes in human liver tumor cell lines, whereas mTOR activation
by Rheb overexpression decreases CD133. Hoshii et al. [56] recently
reported that in a mouse model of acute myeloid leukemia, raptor
deficiency suppresses mTORC1 and leukemia progression. However,
acute myeloid leukemia cells lacking mTORC1 activity still can self-
renew as stem cells survive for a long time, indicating that the inhibition
of mTOR signaling may induce tumor dormancy.
Each year, nearly 30,000 men who had undergone surgery or
radiation for their PCa die from incurable metastatic disease that will
present as lesions in the bone years after curative treatment. Logi-
cally, most, if not all, of the metastases that develop after a protracted
period must have disseminated to bone before surgery or radiation.
How circulating tumor cells traffic to the BM and how PCa cells
become dormant and ultimately overcome dormancy to proliferate
remain critical questions. Our work tested the hypothesis that if
DTCs are engaged in the HSC niche, then the signals generated
by engaging the niche should facilitate the development of dormant
disease. We found that TBK1 interacts with mTOR and inhibits its
function. mTOR inhibition induces the cell cycle arrest of PCa cells
and enhances chemotherapeutic resistance of PCa cells. As a result,
the knockdown of TBK1 decreases PCa stem-like cells and drug
resistance in vitro and in vivo. Taken together, these results strongly
indicate that TBK1 plays an important role in establishing dormancy
and maintaining drug resistance of PCa.
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